More and more biosimilars enter the market raising questions around pricing, regulations, but also how to convince physicians to start using biosimilars, and how to switch the patients.
This is an excerpt from a panel discussion with Jim Roach of Momenta Pharmaceuticals, Inc., Irena Royzman of Patterson Belknap Webb & Tyler LLP, Sophie Opdyke of Pfizer, Chrys Kokino of Mylan, and was moderated by John Farah of Red Team Associates. This panel of experts shed light on the following topics:
- The benefits and risks associated with bringing biosimilars into the U.S. market.
- What do we need to do to accelerate the timeframe of how we accept biosimilars in the U.S.?
- Because of the high costs, how do we increase support to get these products into the country?